{"id":"influenza-vaccine-gsk2340274a","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an influenza vaccine candidate, GSK2340274A works by presenting influenza viral antigens to the immune system to generate protective antibody and T-cell responses. This enables the body to recognize and mount a rapid immune defense against natural influenza infection. The specific formulation and adjuvant strategy of GSK2340274A are proprietary to GlaxoSmithKline's vaccine development program.","oneSentence":"GSK2340274A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:16:04.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention"}]},"trialDetails":[{"nctId":"NCT01051661","phase":"PHASE3","title":"Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-12","conditions":"Influenza","enrollment":6154},{"nctId":"NCT01114620","phase":"PHASE4","title":"Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":"Influenza","enrollment":50},{"nctId":"NCT00989612","phase":"PHASE2","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT01059617","phase":"PHASE1","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-09","conditions":"Influenza","enrollment":133},{"nctId":"NCT01035749","phase":"PHASE2","title":"Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Influenza","enrollment":310},{"nctId":"NCT01001169","phase":"PHASE2","title":"Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT00979407","phase":"PHASE3","title":"Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Influenza","enrollment":336},{"nctId":"NCT00985673","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":611},{"nctId":"NCT00979602","phase":"PHASE3","title":"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Influenza","enrollment":4048},{"nctId":"NCT00985088","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-11","conditions":"Influenza","enrollment":1343},{"nctId":"NCT00976820","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":"Influenza","enrollment":323},{"nctId":"NCT01236040","phase":"PHASE1","title":"Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-29","conditions":"Influenza","enrollment":521},{"nctId":"NCT01008956","phase":"PHASE2","title":"Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Influenza","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Influenza vaccine GSK2340274A","genericName":"Influenza vaccine GSK2340274A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340274A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus antigens. Used for Influenza prevention.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}